文献速递神经介入DSA

新型血流导向装置(FloWise)治疗颈内动脉动脉瘤:一项先导性临床研究结果

A Newly-Developed Flow Diverter (FloWise) for Internal Carotid Artery Aneurysm: Results of a Pilot Clinical Study.
PubMed 文献 · Korean J Radiol · 2019-01-01

这项先导性临床研究纳入10例患者共14个颈内动脉动脉瘤,评估新型可回收血流导向装置FloWise的安全性和有效性。FloWise放置全部成功,6个月临床随访期间无新发神经功能缺损;9例患者12个动脉瘤完成6个月血管造影随访,其中10个(83.3%)体积缩小超过50%,8个(66.7%,95%CI 35.4-98.0%)完全闭塞。作者认为FloWise似乎安全有效,值得开展前瞻性多中心研究验证。

要点

  • 6个月血管造影随访中,10/12个动脉瘤(83.3%)体积缩小超过50%,平均体积缩小82.8±32.9%。
  • 8/12个动脉瘤(66.7%,95%CI 35.4-98.0%)实现完全闭塞。

核心结论

  • 在这项先导性研究中,FloWise似乎对颈内动脉动脉瘤的治疗安全有效,值得开展前瞻性多中心研究以验证其有效性和安全性。

研究设计与样本

  • 先导性临床研究,纳入10例患者共14个颈内动脉动脉瘤,入组时间为2016年1月至2017年7月。

诊断标准与关键数值

  • 纳入标准为:颈内动脉处未破裂动脉瘤且瘤顶尺寸≥8 mm、瘤颈尺寸≥4 mm,或颈内动脉处两个及以上任何尺寸的未破裂动脉瘤且可被单个FloWise覆盖。共同主要有效性终点为FloWise放置的技术成功和6个月随访血管造影中动脉瘤体积缩小≥50%;主要安全性终点为治疗后持续超过1个月的新发神经功能缺损。

临床应用与阅片要点

  • 作者认为FloWise似乎对颈内动脉动脉瘤的治疗安全有效。
  • 作者提出值得开展前瞻性多中心研究以验证FloWise的有效性和安全性。

局限性

  • 原文结论指出这是一项先导性研究(pilot study)。
  • 原文结论提出值得开展前瞻性多中心研究以验证FloWise的有效性和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: We report the results of a pilot clinical study that evaluated the safety and efficacy of a newly-developed, retrievable flow diverter (FloWise; Taewoong Medical) for the treatment of internal carotid artery (ICA) aneurysm.

MATERIALS AND METHODS: A total of 10 patients were enrolled. Inclusion criteria were 1) unruptured aneurysm with a dome size of ≥ 8 mm and a neck size of ≥ 4 mm at the ICA, or 2) two or more unruptured aneurysms of any size able to be spanned by a single FloWise at the ICA. Co-primary effectiveness end points were technical success of FloWise placement, and a 50% or greater decrease in aneurysm volume at the 6-month follow-up angiogram. The primary safety end point was the new development of neurological deficits persisting for more than 1-month post-treatment.

RESULTS: Ten patients harboring 14 ICA aneurysms (median diameter, 9.4 mm; range, 2.3-31.0 mm) were enrolled between January 2016 and July 2017. FloWise placement was successful in all patients. There were no newly-developed neurological deficits during the 6-month clinical follow-up period. One patient did not receive follow-up imaging due to pregnancy. Nine patients with 12 aneurysms received a 6-month angiographic follow-up. Ten aneurysms (83.3%) showed decreases in volume greater than 50% (mean volume decrease, 82.8 ± 32.9%), of which 8 (66.7%, 95% confidence interval, 35.4-98.0%) showed complete occlusion. One patient was retreated due to mass symptom aggravation.

CONCLUSIONS: In this pilot study, FloWise appeared to be safe and effective for ICA aneurysm treatment. A prospective multicenter study to validate the effectiveness and safety of FloWise would be worthwhile.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Kim BM, Park KY, Lee JW, et al. A Newly-Developed Flow Diverter (FloWise) for Internal Carotid Artery Aneurysm: Results of a Pilot Clinical Study. Korean J Radiol. 2019. PMID: 30799582. doi:10.3348/kjr.2018.0421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。